Organization
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA
4 abstracts
Abstract
Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy.Org: Division of Oncology, Rambam health care, Haifa, Israel, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel,
Abstract
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Guardant Health, Inc., Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).Org: Moffitt Cancer Center, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, IBM Watson Health, H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Institute,
Abstract
Engagement of patient participation in genomics research by the Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network.Org: Dana-Farber Cancer Institute, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Broad Institute of MIT and Harvard,